Analysis of Drugs of Abuse in Biological Specimens

Koichi Saito,* Rieko Saito, Yuu Kikuchi, Yusuke Iwasaki, Rie Ito, and Hiroyuki Nakazawa

Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142–8501, Japan

(Received September 1, 2011)

Recent reports of the analysis of drugs of abuse in biological specimens are reviewed herein. Different perspectives from reviews so far published and the need for and the background of drug analysis in biological specimens, and difficulty of drug testing in biological specimens are introduced. Comprehensive biological specimens for the analysis of drugs of abuse in forensic science, including oral fluid (saliva), hair, umbilical cord, meconium, cadaver tissue (brain, adipose), sweat, breath, and nail clippings, in addition to the commonly used blood and urine specimens in clinical chemistry, are described along with their outlines, advantages/disadvantages, and actual examples. Today, liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the method of choice for the analysis of drugs of abuse. A simultaneous screening method for multiple types of drugs has also become popular recently. However, because qualitative determination remains important in forensic science, gas chromatography-mass spectrometry (GC-MS) is still in use even if it requires complicated specimen preparation and derivatization procedures. This is because GC-MS is reliable and has been employed ever since for the appraisal of trials.

Key words—— drug of abuse, forensic science, biological specimen, liquid chromatography-tandem mass spectrometry, gas chromatography-mass spectrometry

INTRODUCTION

Drugs are classified into legal drugs and illegal (or illicit) drugs, and the abuse of drugs has become one of the most serious social problems in the world. In Japan, 32 psychotropic substances were listed as designated substances by the Pharmaceutical Affairs Law in April 2007 to prevent abuse of those substances. Subsequently, other psychoactive compounds were added and as of July 2009, 40 substances are listed as designated substances. However, an annual survey has indicated that new designer drugs still find their way into illegal drug markets.1)

The Japanese government is looking into specifying the part of a chemical structure that produces a narcotic effect and regulating drugs having chemical structures similar to those of abused drugs, as narcotics. However, the problem of designer drugs cannot be solved to this day. Clearly, there is an urgent need to develop analytical methods that would identify such drugs in order to prevent the increasing incidence of drug abuse. Major representative abused drugs are designated as narcotics or stimulants and the possession of such drugs is regulated.

Numerous publications have described the analysis of amphetamine-like drugs and demonstrated the significance of improving the methods of analysis of such drugs in biological specimens. In the last decade, liquid chromatography coupled to mass spectrometry (LC-MS) has seen rapid development for forensic and clinical applications.2–4) LC-MS offers high sensitivity and specificity and reduces the specimen preparation time compared with gas chromatography-mass spectrometry (GC-MS) because relatively non-volatile compounds can be analyzed and no derivatization is necessary.

Many reviews have focused on the drugs of abuse themselves,5–8) specific biological specimens, such as hair,9, 10) the methodology11, 12) or the analytical instruments.2–4)

In this review, on the basis of reports published in the last three years (2008–2010) describing the
analyses of drugs of abuse in biological specimens, different perspectives, such as the need for and the background of drug analysis in biological specimens, and difficulty of drug testing in biological specimens, are introduced together with some actual examples. Furthermore, comprehensive biological specimens for the analysis of drugs of abuse in forensic science, including oral fluid (saliva), hair, umbilical cord, placenta, meconium, cadaver tissue (brain, adipose), sweat, breath, and nail clippings, in addition to the commonly used blood and urine specimens in clinical chemistry, are described along with their outlines. At that time, amphetamines, cocaine, opiates, and cannabis were selected as the target drugs because they are the most frequently used illicit drugs.

NEED FOR AND BACKGROUND OF DRUG ANALYSIS IN BIOLOGICAL SPECIMENS

Drug analysis in biological specimens, such as urine, hair, blood, sweat, or oral fluid (saliva), which is used to determine the presence or absence of specified parent drugs or their metabolites, is necessary in forensic science. The background of drug analysis in biological specimens is shown below.

Testing for Drugs of Abuse in Saliva of Drivers

In forensic science, the study of the detection of drugs of abuse extends to different fields. In the interest of road safety, driving under the influence of drugs has social and legal repercussions and is a cause of grave concern. Drugged drivers pose a serious threat to other drivers as well as to themselves. To obtain information about drug abuse in drivers, a comprehensive screening test for such drugs is necessary, even under normal situations where the drivers are not involved in any accidents.

In Sweden, a person’s driving license is suspended after being convicted for petty drug offense or driving under the influence of drugs. To regain the license, the person has to prove that he or she has been drug-free during a specified observation period. Reliable oral fluid screening devices for onsite screening of drugged drivers are both useful and convenient for maintaining road safety.

Fernández et al. screened 632 saliva specimens collected from drivers in Catalonia, Spain for drugs of abuse through an immunoassay test (Cozart kit; Cozart Bioscience Ltd., Abingdon, UK) and the drugs detected by the screening test were cocaine, cannabis (Δ⁹-tetrahydrocannabinol), opiates (6-monoacetylmorphine), amphetamine, and metamphetamine. Specimens that were tested positive were subjected to GC-MS for confirmation. As a result, more than 80% of the specimens were positive for a combination of two drugs. The most common combination was cocaine and cannabis.

Workplace Drug Testing

Workplace drug testing is a well-established application of forensic toxicology and its aim is to reduce workplace accidents caused by employees who are working under the influence of drugs or alcohol. Several drugs of abuse may be involved, including alcohol, amphetamines, cannabis, cocaine, opiates, and prescription drugs, such as benzodiazepines. The use of alternative biological specimens, such as hair, oral fluid or sweat, in workplace drug testing presents several advantages over urinalysis, mainly because specimen collection can be performed easily without infringing on the workers’ privacy. However, the drugs are usually present in these alternative specimens at low concentrations and the amount of specimen available for analysis is small. In this regard, the use of highly sensitive techniques is necessary.

Drug Abuse among College Students

Drug abuse among college students is characterized by low academic performance and long-term negative consequences. Screening for students who are at a high risk of drug abuse is of primary importance to ensure early identification and appropriate care.

The study of García-Jiménez et al. aimed to determine current or past use of drugs of abuse through a questionnaire distributed to students at the Universidad Autónoma del Estado de Morelos. The actual test results of that study showed that 16% of the specimens were positive for Δ⁹-tetrahydrocannabinolic acid-A (Δ⁹-THCA-A). The results were not different from those of the National Questionnaire on Addiction. On the basis of that finding, they established a program for detecting drug abuse in students. This type of study is important in order to implement programs to decrease the incidence of drug abuse in college students.

Drug-induced Seizures

Approximately 6% of new-onset seizures are
said to be drug-related. However, there is currently no reliable way to determine whether a seizure is indeed drug-induced or not. Drees et al. investigated whether the results obtained by liquid chromatography-tandem mass spectrometry (LC-MS/MS) from a seizure panel could affect patient care as LC-MS/MS is a powerful tool that allows the simultaneous detection of numerous analytes of diverse chemical nature in patient specimens. On analysis of 157 serum or plasma specimens from patients who underwent seizures, 17 were found to be positive for a drug of abuse on the seizure panel. The team of experts determined that the test results probably or definitely would have affected treatment in seven of those cases. Therefore, a test that detects the presence of drugs implicated in drug-induced seizures can help physicians determine if an unexplained seizure is drug-related, thus leading to potentially better direct patient care.

Body Packing

The illicit transport of cocaine and heroin, either swallowed or inserted into the rectum and/or vagina of individuals, which is defined as “body packing,” is becoming an increasingly common occurrence. The assessment of smuggling by body packers through urinalysis has been little reported and on-site rapid screening methods are essentially lacking. Marchei et al. screened for cocaine and heroin metabolites in the urine specimens of suspected body packers with an on-site immunochromatographic test and confirmed the obtained results by GC-MS and X-ray examination. From the obtained results, the on-site detection of cocaine and heroin metabolites in the urine specimens of suspected body packers appears to be a reliable screening test to disclose internally concealed drugs and justify subsequent radiological investigations.

DIFFICULTY OF DRUG TESTING IN BIOLOGICAL SPECIMENS

When a drug is taken, the drug itself and/or its metabolites are excreted in the urine. Urinary concentration corresponds to the non-metabolized drug and its metabolites at the time of specimen collection. Meanwhile, hair is known to reflect the accumulation of drugs. Thus, in the case of an arrest for drug abuse, “use up to the last minute” can be determined by analyzing urine specimens and chronic use over the past few months can be determined by analyzing hair specimens.

In Japan, news of drug abuse among celebrities has appeared. Some have tried to conceal past use of drugs by cutting their hair. The difficulty of drug testing in biological specimens arises from not only the technical problem that the residual level is extremely low, but also the problem of multiple drug use and thus, the test results may not match the self-report made by such abusers of the drugs they used.

Discrepancies between simple test methods, such as biological assays, and the self-report of illicit drug use could undermine epidemiological research findings. Ledgerwood et al. examined the extent of agreement between self-reported illicit drug use and the results of hair analysis in a community sample of middle-aged men and tried to identify factors that may be used to predict the discrepancies between self-report and hair analysis. Hair specimens were analyzed for marijuana, cocaine, opiates, phencyclidine, and methamphetamine using radioimmunoassay (RIA) and GC-MS techniques. As a result, self-report and the results of hair analysis generally showed good, but not excellent, agreement.

BIOLOGICAL SPECIMENS COMMONLY USED IN FORENSIC SCIENCE

Blood and urine are the typical specimens for analysis in clinical chemistry. However, in addition to these, a variety of biological specimens are analyzed in forensic science. In this review, as the major specimens used in the analysis of drugs of abuse for the period of 2008–2010, blood, urine, oral fluid (saliva), hair, umbilical cord, placenta, meconium, tissue (adipose and brain), sweat, nail clippings, and breath will be taken up.

Urine

There are a great many studies that use urine as the biological specimen. As drugs for analysis, amphetamine-type stimulants and cocaine and its metabolites have been used. Amphetamine-type stimulants, such as amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA), are known as central nervous system stimulants and their abuse has recently increased throughout the world.
It is presumed that the increase in the number of drug analysis examples is correlated to the increase in the number of criminal cases related to drug abuse. Notable progress in the overall analysis of drugs of abuse in biological specimens would be the fruit of the development of numerous LC-MS (MS) methods. The successful interface of LC-MS has brought new light to bioanalytical and forensic sciences as it allows the detection of drugs and metabolites at concentrations that are difficult to analyze with commonly used GC-MS based techniques.¹⁶

LC-MS/MS has become very popular and today, it is the leading tool for the simultaneous multicomponent analysis of drugs of abuse. However, in the analysis of amphetamine-type stimulants in urine specimens in particular, a method that uses GC-MS and requires either acetylation or perfluoro-phenyl)-1-methylethylamine (ALEPH) series,³²) the 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine (2C-T) series,³¹) the 2-(2,5-dimethoxy-4-methanesulfonyl-phenyl)-1-methylthylamine (ALEPH) series,³²) and cannabinoid³³) analysis have been reported. As other examples of urinalysis, the 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine (2C-T) series,³¹) the 2-(2,5-dimethoxy-4-methylsulfanyl-phenyl)-1-methylthylamine (ALEPH) series,³²) and cannabinoid³³) analysis have been reported. The 2C-T series and the ALEPH series are psychedelic phenethylamines of the 2C family. 2C is a general name for the family of psychedelic phenethylamines containing methoxy groups on hydroxylated and further to minor metabolites, such as \( m \)-hydroxybenzoylalanine. Cocaine is also metabolized to norcocaine. Cocaethylene is formed when cocaine and ethanol are taken simultaneously. Anhydroecgonine methyl ester is a unique marker in cocaine smokers, and anhydroecgonine ethyl ester is found in cocaine smokers who also use ethanol.

Numerous methods are available for the identification of cocaine or its metabolites in urine.²⁷⁻²⁹) Langman et al.²⁸ developed an LC-MS/MS method for the detection and quantitation of cocaine, benzoylalanine, norcocaine, cocaethylene, \( m \)-hydroxybenzoylalanine, anhydroecgonine methyl ester, and anhydroecgonine ethyl ester in urine. Urine specimens (200 individuals) were cleaned by solid-phase extraction (SPE) and then subjected to LC-MS/MS measurement and confirmation by GC-MS. The results of GC-MS and LC-MS/MS measurements of cocaine and benzoylalanine showed good correlation.

Shakleya et al.³⁰) reported that opiates, cocaine, and their metabolites were quantified by LC-MS in 284 urine specimens collected thrice weekly, to monitor possible drug relapse in 15 drug-dependent pregnant women. As a result, 165 urine specimens (58%) from all the 15 subjects were positive for one or more cocaine analytes. Egonine methyl ester and/or benzoylalanine were the major cocaine biomarkers in 142. Anhydroecgonine methyl ester, a biomarker in cocaine smokers, was positive in six and cocaethylene and/or egonine ethyl ester, biomarkers of cocaine and ethanol co-ingestion, were found in 25.

A simple deproteinization step involves mixing each specimen with an acetonitrile-standard mixture.²⁹) The method has excellent precision across a wide linear range (i.e., 25–2000 ng/ml) for each analyte. Clearly, the LC-MS/MS method for urinalysis is a significant improvement over conventional GC-MS methods. Another point of interest is that different patterns of cocaine biomarkers were observed after LC-MS as compared to GC-MS analysis.

As other examples of urinalysis, the 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine (2C-T) series,³¹) the 2-(2,5-dimethoxy-4-methylsulfanyl-phenyl)-1-methylthylamine (ALEPH) series,³²) and cannabinoid³³) analysis have been reported. The 2C-T series and the ALEPH series are psychedelic phenethylamines of the 2C family. 2C is a general name for the family of psychedelic phenethylamines containing methoxy groups on
positions 2 and 5 of the benzene ring. 2C-T-4 is the 2-carbon homologue of ALEPH-4 and its full chemical name is 2-(isopropylthio)-2,5-dimethoxyphenylethanamine. The structural and pharmacodynamic properties of 2C-T-4 are similar to those of 2C-T-7 and 2C-T-9.

An analytical procedure for the simultaneous determination of four thiophenethylamine designer drugs (2C-T series) in human urine has been reported. Quantitative analysis was performed by capillary electrophoresis with mass spectrometry (CE-MS), using 2,5-dimethoxy-4-methylthiophenethylamine-D₄ as the internal standard. In order to minimize interference by matrix components and preconcentrate the target analytes, SPE was introduced as a cleanup step. The method was validated according to international guidelines and demonstrated to be specific, sensitive, and reliable for the analysis of these derivatives in urine specimens.

Hidvegi et al. tried to identify cannabigerol (CBG), which, in its acid form, is one of the main intermediates in the biosynthesis of cannabinoids in hemp, in urine specimens of confirmed cannabis users. It was shown that enzymatic hydrolysis is necessary for the formation of free neutral cannabinoids from conjugates. After extraction, derivatization with N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) and/or bis-trimethylsilyl derivatization, GC-MS was performed for the identification of CBG and its metabolites in the urine specimens. It was shown that CBG enters the body through cannabis smoking and is excreted in urine in the conjugated form, similar to other neutral cannabinoids. The presence of CBG metabolites, such as its glucuronated form, was examined by analyzing the chromatograms of hydrolyzed and trimethylsilylated extracts.

**Oral Fluid (Saliva)**

Some problems arise when urine specimens are collected at several occasions. For instance, the risk of manipulation and the risk of false-negative urine specimens are high. In addition, many suspected drug users find it difficult or embarrassing to urinate while being observed.

The collection of oral fluid for drug analysis is easy and non-invasive. Oral fluid has demonstrated its usefulness for the analysis of drugs of abuse. Laboratory tests of oral fluid for drugs of abuse have continued to expand in the workplace as well as in legal and medical settings. One of the purposes is to evaluate physical alterations in individuals suspected to be under the influence of drugs.

For instance, oral fluid is gaining prominence as an alternative matrix for monitoring drugs of abuse in the workplace, investigating criminal cases, and screening drivers who may be driving under the influence of drugs. There is a great need for a reliable and rapid on-site oral fluid test that can be used by police authorities to detect drivers suspected of being under the influence of drugs or alcohol. The European Driving under the Influence of Drugs, Alcohol and Medicines (DRUID) project called for the analysis of oral fluid specimens collected randomly and anonymously at the roadside from drivers in Denmark from 2008 through 2009.

On the other hand, significant development has occurred in oral fluid drug analysis in the last few years. New pharmacokinetic studies have been conducted, optimal cutoffs have been proposed, and new studies have examined the correlation between oral fluid drug concentration and impairment.

A recent study, e.g., the detection of THC-COOH in oral fluid, can contribute to resolving the issue of false-positive results caused by passive exposure to marijuana.

Analytical methods for measuring multiple licit and illicit drugs and metabolites in oral fluid require high sensitivity, specificity, and accuracy. As the volume available for analysis is limited, a comprehensive method is needed for the simultaneous measurement of multiple analytes in a single aliquot.

For instance, Fritch et al. reported the validation of a semi-automated method for the simultaneous extraction, identification, and quantitation of 21 analytes in a single oral fluid aliquot. The target compounds were amphetamine, methamphetamine, MDA, MDMA, 3,4-methylenedioxymethamphetamine (MDMA), pseudoephedrine, cocaine, benzoylecgonine, codeine, norcodeine, 6-acetylcocaine, morphine, 6-acetylmorphine, hydrocodone, norhydrocodone, dihydrocodeine, hydromorphone, oxycodone, noroxycodone, oxymorphone, and phencyclidine. Oral fluid specimens were collected with the Intercept™ device (OraSure Technologies, Inc., Bethlehem, PA, USA) and subjected to SPE. Thirty-nine patients were tested positive for various combinations of licit and illicit drugs and their metabolites.

There are many reports of the use of LC-MS/MS for oral fluid specimens. A screening system to analyze multiple drugs simultaneously has been...
come the mainstream. In this regard, matrix effects should be taken into consideration. Although ion suppression and enhancement were observed for cocaine, opiates, and their metabolites, the performance of the LC-MS/MS method was not influenced by matrix effects when deuterated internal standards were used.40)

In the case of urinalysis, in addition to LC-MS/MS, recently, rapid test kits, such as immunoassay, have been widely used.14,41) The target drugs of the test kits are marijuana, methamphetamine, cocaine, opiates, and so on. However, most of the target drugs require confirmatory tests by LC-MS/MS and/or GC-MS, in case the immunoassay gives positive results.

So far, urine and saliva are the major specimens for the analysis of drugs of abuse. However, sometimes, the use of both seems to be best. For example, tests for sports doping fall under this category.

Stimulants are banned by the World Anti-Doping Agency (WADA) if used “in competition.” As the analysis of stimulants is presently carried out on urine specimens only, for better interpretation of analytical data, it may be useful to discriminate between early intake of the stimulant and administration specifically aimed at improving sport performance.

Strano-Rossi et al.42) investigated differences in the excretion/disappearance of drugs between urine and oral fluid, a specimen that can reflect plasma concentration. As a result, both the absolute concentrations and their variations as a function of time were markedly different between urine and oral fluid; drugs were eliminated much more slowly from urine than from oral fluid.

In all those cases, the concentration of a drug metabolite in urine was very low and the parent compound was not detected at all. It was suggested that it is indeed impossible to discriminate between recent administration of small doses and past administration of larger doses, if one relies on only urine data. In addition, the results also suggested that the analysis of oral fluid could be used to successfully complement data obtained from urinalysis.

**Hair**

Urine or saliva sampling is noninvasive and has been widely used because of ease of collection. However, the main disadvantage of urinalysis is the short window of detection. On the other hand, hair is becoming as important as urine and saliva as the specimen used in drug analysis.9,10)

Hair has become an important matrix for drug analysis, complementing blood and urine specimens. The prolonged detection window makes hair analysis suitable for the detection of exposure to illegal drugs for a period of up to 12 months.43) Hair sampling, which features easy sampling and minimal risk of manipulation, may therefore be a welcome alternative. The prolonged detection window may also provide more reliable information to the physician.44)

In order to evaluate the usefulness of hair specimens and investigate practical and interpretive problems or advantages with the use of hair specimens, Kronstrand et al.15) conducted hair analysis for drugs prior to re-issuing drivers’ licenses as a Swedish pilot study. Ninety-nine hair specimens and 198 urine specimens were collected from 84 individuals during the 12-month study period. The hair specimens were screened for 20 drugs with LC-MS/MS and confirmation of positive results was accomplished with GC-MS or LC-MS/MS. As a result, hair analysis identified illegal drugs in seven different occasions, whereas urinalysis failed to identify any illegal drugs in all occasions. This indicates that the physician must have an understanding and knowledge of the limitations of the screening methods used.

An LC-MS/MS method was developed for the determination of ketamine (and its metabolite nor-ketamine) and some amphetamines (amphetamine, methamphetamine, MDA, and MDMA). Hair specimens were washed and pulverized and then extracted with aqueous formic acid solution. Deuterated analogs of the analytes were used as internal standards for quantification. The analysis by LC-MS/MS was simpler and faster than that by conventional GC-MS methods that usually require more laborious extraction procedures and, in most cases, an additional derivatization process.45)

As hair cocaine concentration is a reliable marker of exposure to the drug, an original liquid chromatographic method has been developed for the determination of cocaine in human hair specimens by HPLC with fluorescence detection.46) The method was validated and successfully applied to hair specimens collected from cocaine users. Specimen pre-treatment was carried out by incubative extraction with 0.1 M HCl, followed by SPE with C2 cartridges. For detection, native cocaine fluorescence was monitored at 315 nm with excitation at 230 nm.
Miller et al. used phosphate buffer (pH 5.0) as the optimum hair incubation medium because of the high stability of cocaine and 6-monoacetylmorphine in this buffer. Then, two different SPE methods [Bond Elut Certify® (Agilent Technologies, Inc., Santa Clara, CA, USA) and Clean Screen® (United Chemical Technologies, Bristol, PA, USA)] were employed for specimen cleanup before LC-MS/MS analysis. However, the matrix effect, demonstrating ion suppression, was observed in most analytes.

As regards the solution for extraction and incubation of hair specimens, other than phosphate buffer, 25 mM formic acid: acetonitrile mixture (5 : 95), 0.1 M HCl, and methanol have been used. Considering the influence of matrix effects, deuterated internal standards were usually added during the specimen extraction procedure.

Cocaine and its metabolites are included in the proposed United States federal regulations for hair analysis. The suggested cut-off concentration for the metabolites is 50 pg/mg, which is difficult to achieve routinely with electron impact GC-MS. This may be due to the inability to derivatize co-cocaine to improve its response and the disturbance in the detection of co-eluted norcocaine and cocaethylene, or potentially similar ions as the derivatives of norcocaine and benzoylecgonine.

Barroso et al. developed and validated an analytical method for the simultaneous determination of cocaine and its main metabolite, benzoylecgonine, in human hair specimens by GC-MS. After extraction of the hair matrix with a mixture of methanol/HCl (2 : 1) at 65°C for 3 hr, followed by specimen cleanup by mixed-mode SPE, the extract was analyzed by GC-MS after derivatization with MSTFA with 5% chlorotrimethylsilane. The developed method may be useful for the analysis of cocaine and benzoylecgonine in hair specimens in forensic toxicology laboratories, taking into account the speed and sensitivity achieved with a single quadrupole MS that is available in most laboratories.

Unlike cocaine, the analysis of amphetamines in hair specimens by GC-MS has been widely practiced. As examples of specimens for analysis using GC-MS, amphetamine-type stimulants and marijuana are mentioned. The procedure involves liquid-liquid extraction of hydrolyzed hair specimens spiked with deuterated internal standards, followed by derivatization with N-methyl-bis(trifluoroacetamide) (MBTFA), heptfluorobutyric anhydride (HFBA), or perfluoroctanoyl chloride.

As regards cannabinoid analysis by GC-MS, a similar alkaline hydrolysis of hair specimens was employed, and for derivatization of the analytes, MSTFA was used for silylation.

Hair analysis in forensic and clinical toxicology has focused on drugs of abuse and comprehensive, drug-class-independent screening methods based on MS have not been applied to date.

Pelander et al. investigated a qualitative basic drug screening method for hair specimens that uses liquid chromatography coupled to time-of-flight mass spectrometry (LC/TOF-MS), which has been developed and evaluated for forensic toxicological urinalysis. The method included alkaline hydrolysis and purification by mixed-mode SPE prior to LC/TOF-MS analysis. Identification was based on accurate mass, isotopic pattern fit, and retention time, if available. The drug classes identified included antidepressants, antipsychotics, antiepileptics, amphetamines, opioids, beta-blockers, a benzodiazepine, a hypnotic, a local anesthetic, an antiemetic, and an antipyretic analgesic.

Analysis of 32 hair specimens from deceased drug addicts revealed the intake of 35 different drugs, and the findings were in good agreement with the findings in blood and urine specimens by other methods. Moreover, information about previous drug use, which is not evident in the analysis of other matrices, was obtained in the majority of the cases. However, one apparent false-positive result was identified.

Two points should be noted when conducting hair analysis. First, discriminative analysis to differentiate the incorporation of abused drugs into hair from external contamination of the hair surface is necessary. Hoelze et al. investigated the utility of discriminative analysis in differentiating between incorporation of cocaine and its congeners into hair and external contamination, when dealing with compounds that are administered by sniffing or inhalation (e.g., cocaine). The statistical discriminant analysis made a prediction for each cocaine-positive hair specimen as regards the likelihood of its belonging to the group of cocaine users or being contaminated.

As the second point, in hair analysis, particularly cocaine analysis, there is a possibility of contamination during sample preparation and hair analysis. In other words, “hair porosity” should be considered in evaluating external contamination. Hill et al. applied a method for determining hair porosity to hair specimens, and the porosity charac-
teristics of hair are discussed in relation to experimental and actual contamination of hair.

**Umbilical Cord, Placenta, and Meconium**

As regards biological specimens specific to pregnant women, the umbilical cord, placenta, and meconium will be discussed as specimens for the analysis of drugs of abuse. The exposure of pregnant women to recreational drugs, that is, in utero drug exposure, may adversely impact fetal and neonatal development. In this regard, detecting drug exposure during pregnancy is the most effective way to improve pre- and post-natal care in the mother and the newborn as it permits implementation of adequate treatment and follow-up.59)

**Umbilical Cord:** The umbilical cord is considered to be a waste product after childbirth. Nevertheless, the umbilical cord also is suitable for anonymous epidemiological studies. Montgomery et al.60) suggested that the umbilical cord could be an alternative to meconium for detecting fetal drug exposure after demonstrating that comparable results were obtained in those two matrices.

De Castro et al.59) developed and validated an LC-MS method for the simultaneous quantification of methadone, cocaine, opiates, and metabolites in umbilical cord tissue. In their method, homogenization of the specimen in acidic conditions and subsequent extraction with mixed-mode cation-exchange cartridges allowed for adequate sensitivity and selectivity for quantification of the analytes of interest.

The quantification of methadone and its metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine in umbilical cord specimens from women receiving known doses of methadone permits determination of potential correlations between drug concentration in the umbilical cord and the administered dose, and whether umbilical cord drug concentration can predict maternal and neonatal outcomes.

In general, umbilical cord tissue is available in abundance and thus specimen acquisition is not an issue. Therefore, the simultaneous determination of other common drugs of abuse will help us understand the usefulness of umbilical cord analysis for the identification of in utero drug exposure.

Jones et al.61) reported the use of LC-MS/MS to confirm amphetamines in umbilical cord specimens presumed to be positive for amphetamine and methamphetamine. The study using matched pairs of meconium and umbilical cord demonstrated a high degree of agreement.

**Placenta:** The placenta may serve as an alternative specimen to urine for testing drugs of abuse during the first trimester of gestation. The advantage of placenta tissue, obtained as discarded material in the event of pregnancy termination, over such conventional matrices as urine and blood is that the collection is almost noninvasive and relatively easy to perform.

Joya et al.62) reported the development and validation of a method for the quantification of drugs of abuse, such as amphetamine, methamphetamine, MDMA, methadone, cocaine, benzoylecgonine, cocaethylene, morphine, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol, nicotine, and cotinine, in human placenta tissue, using GC-MS. Placenta specimens were stored at −80°C until analysis and the analytes were stable even after three freeze-thaw cycles (stored at −20°C). The analytical method was used to evaluate the effect of the consumption of drugs of abuse in women who voluntarily terminated their pregnancy at the 12th week of gestation. The use of placenta as a non-conventional matrix showed that it was able to provide information about early in utero exposure to the drugs of abuse.

In another study, cocaine and its metabolites, and opiates in placenta have also been analyzed by LC-MS/MS. A method for the simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by LC-MS was developed by De Castro et al.63) Specimens were homogenized and subjected to SPE in the conventional manner. The applicability of the method was demonstrated in the analysis of five placenta specimens from opioid-dependent women receiving methadone pharmacotherapy, with methadone doses ranging from 65 to 95 mg on the day of delivery. The detection of drugs of abuse in the placenta may also improve knowledge of the usefulness of this matrix for detecting in utero drug exposure and studying the disposition of drugs in the maternal-fetal dyad.

**Meconium:** The meconium offers several advantages for detecting prenatal drug exposure and has become the specimen of choice for the past two decades. Accumulating substances from the 12th gestational week until birth, the meconium acts as a reservoir for exogenous compounds, such as drugs and metabolites. Drugs are incorporated into the meconium via fetal biliary excretion or through ingestion of drug-contaminated amniotic fluid. Meconium analysis is thought to enable the
detection of maternal drug use during the second and third trimesters of pregnancy, whereas neonatal hair and urine analyses indicate more recent exposure. Meconium is usually passed in the first 1 to 3 days of life but may be delayed in premature infants. Its complex composition of mucopolysaccharides, water, bile salts, bile acids, epithelial cells, and other lipids makes drug isolation difficult.64)

Reviews by Gray et al.65) summarize current literature on meconium analysis. A brief overview is provided as follows: illicit drugs, therapeutic drugs, ethanol metabolites, pesticides, and other xenobiotics have been detected in meconium using conventional toxicological techniques, including immunoassay, and confirmed by GC-MS or LC-MS.

As regards analytical methodology, because of the complexity of the meconium matrix, extraction and specimen preparation prior to instrumental analysis may prove difficult and time-consuming. Gunn et al.65) described a method for the rapid extraction and quantification of amphetamine and methamphetamine from meconium, which uses SPE (ISOLUTE® HM-N supported liquid extraction columns containing a modified form of diatomaceous earth; Biotage Inc., Charlottesville, VA, USA) and GC-MS.

Lopez et al.66) reported the case of a newborn with symptoms of hyperexcitability. After it was confirmed that the mother had consumed drugs during pregnancy using an enzyme multiplied immunoassay technique, the newborn’s urine and meconium specimens were analyzed by GC-MS. A GC-MS method for the simultaneous analysis of cocaine, benzoylecgonine, codeine, morphine, and 6-acetylmorphine in meconium is described. Confirmation of urine and meconium results by GC-MS showed consumption of cocaine and codeine during pregnancy and the gradual decline of the levels of those drugs in the newborn, totally disappearing by the third day of life.

Gunn et al.67) described the simultaneous determination and quantification of cocaine and its major metabolite, benzoylecgonine, in meconium using ultra performance liquid chromatography (UPLC)-MS/MS. The extraction of cocaine and benzoylecgonine from the homogenized meconium matrix was achieved with a preliminary protein precipitation or protein “crash” procedure employing cold acetonitrile, followed by mixed-mode SPE. Following elution from the SPE cartridge, the eluents were concentrated and injected onto the UPLC-MS/MS for analysis.

**Tissue (Brain, Adipose)**

**Brain Tissue:** Postmortem drug screening in cases of presumed overdose as cause of death is routinely carried out in toxicology laboratories. The most common specimen used for the analysis is blood due to its temporal relation with the effect of a drug on the individual and his/her status at the time of death. Other specimens, such as vitreous humor, saliva, and urine, are also analyzed to complement blood analysis or in cases where blood extraction is difficult for certain reasons.

There are solid data demonstrating that drugs and their metabolites distribute mainly in tissues rich in lipids, including brain and adipose. Brain tissue provides excellent information relevant to the status of the individual and the possible physical alterations and conduct at the time of death.68) The analysis of brain tissue specimens may provide such valuable information as the type of drug administered when a postmortem investigation is carried out to determine the potential cause and manner of death.69)

In the analysis of brain tissue specimens, SPE is carried out, followed by the semi-quantitative determination of cocaine levels by GC-MS/MS using deuterated cocaine as the internal standard.68)

Shakleya et al.69) developed an LC-MS/MS method for isolating drugs of abuse, such as cocaine, benzoylecgonine, cotinine, ecgonine methyl ester, 6-acetylmorphine, trans-3-hydroxycotinine, codeine, and nicotine, in brain tissue specimens.

On the other hand, Reich et al.70) pointed out the difficulty of detecting drugs in brain tissue, which typically requires extensive specimen preparation followed by drug extraction before the extracts are finally analyzed by LC-MS. Therefore, in order to eliminate any complications introduced by specimen pretreatment, a method for directly analyzing drugs in intact tissue was developed.

Matrix-assisted laser desorption/ionization tandem mass spectrometry [MALDI-MS(n)] demonstrated the ability to quantify cocaine present in postmortem brain tissue of a chronic human cocaine user.70)

**Adipose Tissue:** Adipose tissue can be used to detect absorbed chemicals in living organisms, provided that the chemicals are highly lipophilic and bind to it.71) In mammals, an increased storage of chemicals in adipose tissue indicates a longer exposure of the tissue to the chemicals even after the cessation of external exposure; that is, chemicals that are adsorbed by the body tend to persist in adipose...
tissue on the basis of their lipophilicity. The extent of chemical accumulation in adipose tissue is correlated with the adipose tissue/blood partition coefficient. For instance, THC is highly soluble in lipids and rapidly distributed in tissues, including adipose tissue.

Adipose tissue is also an optimal specimen in cases with extended postmortem time lag and whenever body fluids cannot be obtained. Similar to hair specimens, adipose tissue provides long-term information about an individual’s drug use, which is especially useful when the history of drug abuse is not easily obtained. Drugs identified in postmortem adipose tissue are accumulated because of antemortem deposition and not any postmortem changes. In this connection, adipose tissue may be an optimal matrix in forensic toxicology.

Unfortunately, adipose tissue is a complex biological matrix that necessitates several preanalytical preparation steps to separate drugs and metabolites from the lipophilic matrix. Adipose tissue is not considered to be an optimal specimen in analytical toxicology, primarily because of the difficulties in specimen handling and processing for cleanup. It is for these reasons that few case reports on drug detection in postmortem adipose tissue have been published.

Colucci et al. developed a GC-MS method for the determination of cocaine, its metabolites, methadone, and morphine in postmortem adipose tissue. The method involves the aqueous acid extraction of analytes, the alkalinization of the extract, SPE with chloroform, and derivatization with N,O-bis(trimethylsilyl)trifluoroacetamide before GC-MS analysis. Deuterated compounds were used as internal standards for the determination and quantification of analytes.

**Sweat, Breath, and Nail Clippings**

Next, relatively minor specimens for the analysis of drugs of abuse are introduced.

**Sweat:** Sweat has attracted attention in recent years as an alternative matrix in forensic toxicology as it can be sampled easily and non-invasively. Sweat can be collected with patches over a long period, thereby permitting drug monitoring over a longer period than urine.

Concheiro et al. developed an LC-MS/MS method for the quantification of buprenorphine, norbuprenorphine, methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, cocaine, benzoylecgonine, egonine methyl ester, morphine, codeine, 6-acetylmorphine, heroin, 6-acetylcodine, cotinine, and trans-3′-hydroxycotinine in sweat specimens. Buprenorphine and methadone are medications used in the clinical setting to help opiate-addicted individuals withdraw from and stop using drugs. Sweat patches were mixed with acetate buffer at pH 4.5 and the supernatant was subjected to SPE (Strata-XC-cartridges, Phenomenex, Inc., Torrance, CA, USA). The method was applied to sweat patches collected weekly from an opioid-dependent buprenorphine-maintained pregnant woman. As a result, buprenorphine, cocaine, opiates, and methadone were detected from the sweat specimens.

**Breath:** Berchtold et al. tried to detect such narcotics as morphine, fentanyl, norfentanyl, naloxone, cocaine, hydroxybutyrolactone, and nicotine from breath. They challenged the diagnosis by online breath analysis using MS, because of the low concentrations of the pertinent compounds in breath.

**Nail Clippings:** Nail clippings were used as analytical specimens for the detection and quantitation of illicit drugs.

Kim et al. developed a GC-MS method for the simultaneous qualification and quantification of amphetamine, methamphetamine, MDA, MDMA, ketamine, and norketamine in nail clippings. Similar to hair analysis, methods for the surface decontamination and extraction of the specimens are critical for the analysis. Water and methanol washes, followed by alkaline hydrolysis and liquid-liquid extraction with ethyl acetate, were selected for use in the study. The extracts were evaporated to dryness, derivatized with HFBA at 60°C for 30 min, and analyzed by GC-MS. The results indicated that nail clippings are potentially useful specimens for the detection of past illicit drug use.

Although it is not a recent report, Lemos et al. demonstrated the analysis of nail clippings for drugs of abuse, i.e., they determined cannabis in the nail clipping specimens by RIA and GC-MS.

**Dried Blood Spot**

For the last section of biological specimens, we would like to discuss “blood.” Blood is the most important and versatile specimen for drug analysis not only in clinical chemistry, but also in forensic science. In fact, in cases of the analysis of drugs of abuse, blood specimens have often been employed in detecting cocaine, amphetamines, and opiates.
| Specimens          | Analytes                        | Pre-treatment (extraction, cleanup, and/or derivatization) | Analysis Instruments | References |
|--------------------|--------------------------------|------------------------------------------------------------|----------------------|------------|
| Urine              | amphetamines, 2Cs              | SPE                                                        | LC-MS                | 21         |
|                    | amphetamines (TMA series)      | SPE                                                        | LC-MS                | 22         |
|                    | amphetamines, ephedrines       | SPE                                                        | GC-MS                | 23         |
|                    | amphetamines                   | filtration                                                 | LC-MS/MS             | 24         |
|                    | amphetamines                   | LLE                                                        | GC-MS                | 25         |
|                    | amphetamines                   | SPE                                                        | GC-MS                | 26         |
|                    | cocaïnes                       | SPE                                                        | LC-MS/MS             | 27         |
|                    | cocaïnes                       | LLE, SPE                                                   | LC-MS/MS             | 28         |
|                    | cocaïnes, cocaïnes, opiates,   | deproteinisation                                           | LC-MS/MS             | 29         |
|                    | amphetamines, cocaïnes, opiates, | no-clean up (direct injection)                           | LC-MS                | 30         |
| 2C-T series        | SPE                            |                                                           | CE-MS                | 31         |
| ALEPH series       | cocaïnes                       | SPE                                                        | CE-DAD               | 32         |
| cannabinoids      | enzymatic hydrolysis, silylation|                                                           | GC-MS                | 33         |
| Oral fluid (saliva)| amphetamines, cocaïnes, opiates, | SPE                                                        | LC-MS/MS             | 35         |
|                    | cannabinoids, benzodiazepines  |                                                            |                      |            |
|                    | amphetamines, opiates          | SPE                                                        | LC-MS/MS             | 37         |
|                    | amphetamines, cocaïnes, opiates| LLE, SPE                                                   | LC-MS/MS             | 38         |
|                    | amphetamines, cocaïnes, opiates, | dilution                                                  | LC-MS/MS             | 39         |
|                    | amphetamines, cocaïnes, opiates, | deproteinisation                                           | LC-MS/MS             | 40         |
|                    | amphetamines, cocaïnes, opiates, | no-clean up                                               | immunoassay, GC-MS   | 14         |
|                    | amphetamines, cocaïnes, opiates, | cocaïnes, cannabinoids                                    | no-clean up          | 34         |
|                    | amphetamines, cocaïnes, opiates, | cocaïnes, cannabinoids                                    | no-clean up          | 41         |
| Hair               | amphetamines, cocaïnes, opiates, | alkaline hydrolysis, SPE                                  | LC-TOFMS             | 43         |
|                    | benzodiazepines, nicotines      |                                                            |                      |            |
|                    | amphetamines, opiates          | acid extraction                                           |                      |            |
|                    | cocaïnes                        | acid extraction                                           | LC-MS/MS             | 45         |
|                    | amphetamines, cocaïnes, opiates, | benzoïdiazepines                                          |                     | 46         |
|                    | benzodiazepines, others         | alkaline hydrolysis, SPE                                  |                     | 47         |
|                    | amphetamines, opiates          | acid extraction                                           |                      |            |
|                    | cocaïnes                        | SPE                                                        | LC-MS/MS             | 48         |
|                    | amphetamines, cocaïnes, opiates, | methanol extraction                                       | LC-MS/MS             | 49         |
|                    | benzodiazepines                 | SPE, silylation                                            | GC-MS                | 51         |
|                    | cocaïnes                        | SPE, alkaline hydrolysis, LLE, acylation                   | GC-MS                | 52         |
|                    | amphetamines                    | alkaline hydrolysis, LLE, acylation                        | GC-MS                | 53         |
|                    | amphetamines, opiates           | LLE, acylation                                             | GC-MS                | 54         |
|                    | amphetamines, cocaïnes, opiates, | SPME, silylation                                          | GC-MS                | 55         |
|                    | cannabinoids                    | SPME                                                        |                      | 56         |
|                    | cocaïnes                        | enzymatic digestion, SPE                                  | LC-MS/MS             | 58         |
| Unbilical cord      | amphetamines                    | SPE                                                        | LC-MS/MS             | 61         |
|                    | opiates, cocaïnes               | SPE                                                        | LC-MS/MS             | 59         |
|                    | amphetamines, cocaïnes, opiates, | no-clean up                                               | immunoassay          | 60         |
| Placenta            | amphetamines, cocaïnes, opiates, | SPE, silylation                                           | GC-MS                | 62         |
|                    | cannabinoids                    |                                                            |                      |            |
|                    | cocaïnes                        | SPE                                                        | LC-MS                | 63         |
|                    | amphetamines, cocaïnes, opiates, | SPE                                                        | LC-MS/MS             | 64         |
|                    | amphetamines                    | SPE                                                        | GC-MS                | 65         |
|                    | cocaïnes                        | SPE                                                        | LC-MS/MS             | 67         |
|                    | cocaïnes, opiates               | no-clean up                                               | immunoassay, GC-MS   | 66         |
|                    | cocaïnes                        | SPE                                                        | GC-MS                | 68         |
|                    | cocaïnes, opiates, nicotines    | SPE                                                        | LC-MS/MS             | 69         |
|                    | cocaïnes                        | no-clean up                                               | MALDI-MS(n)          | 70         |
| Tissue (Brain)      | amphetamines                    | SPE                                                        | LC-MS/MS             | 64         |
|                    | cocaïnes, opiates               | SPE                                                        | GC-MS                | 65         |
|                    | cocaïnes, opiates, nicotines    | SPE                                                        | LC-MS/MS             | 67         |
|                    | cocaïnes, opiates, nicotines    | no-clean up                                               | immunoassay, GC-MS   | 66         |
|                    | cocaïnes                        | SPE                                                        | GC-MS                | 68         |
|                    | cocaïnes, opiates               | SPE                                                        | LC-MS/MS             | 69         |
| Tissue (Adipose)    | amphetamines, opiates           | SPE, silylation                                            | GC-MS                | 71         |
|                    | cocaïnes, opiates, nicotines    | SPE                                                        | LC-MS/MS             | 72         |
|                    | cocaïnes                        | SPE                                                        | MS                   | 73         |
| Sweat              | amphetamines, opiates           | SPE, silylation                                            | LC-MS/MS             | 74         |
| Breath             | cocaïnes                        | SPE                                                        | MS                   | 75         |
| Nail clippings     | amphetamines, opiates           | SPE, silylation                                            | GC-MS                | 76         |
| Blood              | cannabinoids                    | SPE, silylation                                            | GC-MS                | 77         |
| Dried blood spot   | cocaïnes                        | SPE                                                        | LC-MS/MS             | 76         |
|                    | cocaïnes                        | SPE                                                        | LC-FL                | 77         |

amphetamines: including amphetamine derivatives and metabolites, cocaïnes: including cocaine derivatives and metabolites, opiates: including natural and synthetic alkaloids, and their metabolites, cannabinoids: including >9-THC and synthetic cannabinoids, 2Cs: a family of psychedelic phenethylamines, 2C-T series: thiophenethylamine designer drugs, ALEPH series: thiophenethylamine designer drugs, TMA series: trimethoxy amphetamines, ephedrines: including related homologues, benzodiazepines: including related homologues, nicotines: including metabolites, LLE: liquid-liquid extraction, SPME: solid-phase microextraction, CE-DAD: capillary electrophoresis with diode array detector, LC-FL: liquid chromatography with fluorescence detector.
However, blood per se is not interesting as a biological specimen. “Impregnated filter paper blood” or the so-called “dried blood spots (DBS),” which increase the shelf life of a drug in blood collected in the field and facilitate transport and storage, are presented here as examples of the analysis.

Alfazil et al. investigated the stability of benzodiazepines and cocaine in DBS. Previous studies have shown that drug concentrations in blood can change during storage especially at room temperature. However, even labile drugs, such as cocaine, may be stable in DBS. A new method has been developed for the analysis of hydrolytically labile drugs in DBS in order to assess their degradation during a storage period of one month. As the test drugs, flunitrazepam, temazepam, oxazepam, lorazepam, nitrazepam, diazepam, and cocaine were selected. A piece of filter paper was spotted with 100 µl of blood containing the drugs at the concentration of 1000 ng/ml and left overnight to dry at room temperature. The drugs were then extracted by suspending the filter paper in phosphate buffer. The extract was subsequently cleaned up by SPE and analyzed by LC-MS/MS. In their experiment, DBS were stored in duplicate at room temperature, 4°C, and −20°C for up to one month. The degradation of the drugs in DBS at all storage conditions was minimal compared to the degradation in the corresponding liquid blood specimens stored under similar conditions and more than 80% of each analyte could be recovered from the specimens.

Mercolini et al. also employed DBS for the analysis of cocaine and its two metabolites by liquid chromatography with fluorescence detection. A solvent extraction technique was implemented for fast and feasible specimen pre-treatment. The method was successfully applied to DBS collected from some cocaine users, both with and without concomitant ethanol intake. The results were in good agreement with those obtained from plasma specimens that were subjected to an original SPE procedure on C8 cartridges. The method was suitable for monitoring cocaine/ethanol use by means of DBS or plasma testing.

CONCLUSION

Various biological specimens have been used in the analysis of drugs of abuse in the field of forensic science, as described in this review. Table 1 shows the overview list of analytical methods for abused drugs in various biological specimens mentioned in this review. Although the analytical techniques used in forensic science are very similar to those used in clinical chemistry as well as pharmacokinetics and metabolic monitoring, there are marked differences in the purpose, specimen, and time required for analysis. In forensic science, because the analytical results greatly affect the outcome of criminal investigations and court decisions, qualitative ability is thought to be more important than quantitative ability. Of course, if cutoff values are set for drugs of abuse, high reliability of the quantitatively determined values is required.

Further advances in analytical instrumentation have paved the way for the development of sophisticated trace analysis methods that enable possible use of a specimen containing trace amounts of a drug and small amounts of specimen, such as hair and nail clippings. In the analysis of drugs of abuse, the proliferation of designer drugs has become a serious problem and there is an ongoing cat-and-mouse game between the police authorities and drug abusers. By further advancing analytical methods for drugs of abuse in the future, it is hoped that drug abuse would be completely eradicated.

REFERENCES

1) Uchiyama, N., Miyazawa, N., Kawamura, M., Kikura-Hanajiri, R. and Goda, Y. (2010) Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008. Yakugaku Zasshi, 130, 263–270.
2) Hoja, H., Marquet, P., Verneuil, B., Lotfi, H., Penicaut, B. and Lachatre, G. (1997) Applications of liquid chromatography-mass spectrometry in analytical toxicology. J. Anal. Toxicol., 21, 116–126.
3) Marquet, P. and Lachatre, G. (1999) Liquid chromatography-mass spectrometry: potential in forensic and clinical toxicology. J. Chromatogr. B Biomed. Sci. Appl., 733, 93–118.
4) Marquet, P. (2002) Progress of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Ther. Drug Monit., 24, 255–276.
5) Yamada, H., Ishii, Y. and Oguri, K. (2005) Metabolism of drugs of abuse: its contribution to the toxicity and the inter-individual differences in drug sensitivity. J. Health Sci., 51, 1–7.
6) Chinaka, S., Iio, R., Takayama, N., Kodama, S. and Hayakawa, K. (2006) Chiral capillary electrophoresis of amphetamine-type stimulants. J. Health Sci.,
17) Garcia-Jimenez, S., Heredia-Lezama, K., Bilbao-Fernández, A., Font, A. M., Fité, M. S., Pagés, M., Fiz, J., Pacifici, R., Zuccaro, P., Barré, M. and de la Torre, R. (2008) Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of “hallucinogenic designer drugs” in urine of consumers. J. Pharm. Biomed. Anal., 47, 335–342.

18) Lee, S. K., Kim, S.-H., Kim, H. J., Yoo, H. H., Kwon, O. S., In, M. K., Jin, C., Kim, D. H. and Lee, J. (2010) Simultaneous qualitative and quantitative method using liquid chromatography selected reaction monitoring-triggered quantitation-enhanced data-dependent tandem mass spectrometry for the identification and classification of amphetamine-type stimulant abusers in human urine. Rapid Commun. Mass Spectrom., 24, 3139–3145.

19) Moawad, M., Khoo, C. S., Lee, S. and Hennell, J. R. (2010) Simultaneous determination of eight sympathomimetic amines in urine by gas chromatography/mass spectrometry. J. AOAC Int., 93, 116–122.

20) Meyer, M. R., Willhelm, J., Peters, F. T. and Maurer, H. H. (2010) Beta-keto amphetamines: Studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylene in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem., 397, 1225–1233.

21) Sun, Q. R., Xiang, P., Yan, H. and Shen, M. (2008) Simultaneous analyses of cocaine and its metabolite benzoylecgonine in urine by LC-MS/MS. J. Forensic Sci., 24, 268–272.

22) Langman, L. J., Bjergum, M. W., Williamson, C. L. and Crow, F. W. (2009) Sensitive method for detection of cocaine and associated analytes by liquid chromatography-tandem mass spectrometry in urine. J. Pharm. Biomed. Anal., 48, 383–387.

23) Nakashima, K. (2008) Hair analysis of drugs of abuse. Bunseki Kagaku, 57, 783–799.

24) Nakashima, K. (2009) Development of ultra sensitive HPLC determination methods for drugs of abuse and their applications to evaluate drug-drug interactions. Chromatography, 30, 57–60.

25) Nakashima, K. (2011) Development and application of sensitive methods with luminescence detections for determination of biologically active compounds. J. Health Sci., 57, 10–21.

26) Nakashima, K., Gunnar, T., Engblom, C., Seppä, H., Juma, A. and Lillig, P. (2008) Roadside oral fluid testing: comparison of the results of drugwipe 5 and drugwipe benzodiazepines on-site tests with laboratory confirmation results of oral fluid and whole blood. Forensic Sci. Int., 175, 140–148.

27) Fernández, A., Font, A. M., Fité, M. S., Pagés, M. B. and Adroher, M. P. (2008) Drugs of abuse in saliva of drivers: medical and legal aspect. Revista Española de Medicina Legal, 34, 3–10.

28) Kronstrand, R., Nystrom, I., Forsman, M. and Kall, K. (2010) Hair analysis for drugs in driver’s license regranting. A Swedish pilot study. Forensic Sci. Int., 196, 55–58.

29) Gallardo, E., Barroso, M. and Queiroz, J. A. (2009) LC/MS: A powerful tool in workplace drugs testing. Drug Test. Anal., 1, 109–115.

30) Garcia-Jimenez, S., Heredia-Lezama, K., Bilbao-Marcos, F., Fuentes-Lara, G., Monroy-Noyola, A. and Deciga-Campos, M. (2008) Screening for marijuana and cocaine abuse by immunoanalysis and gas chromatography. Ann. N. Y. Acad. Sci., 1139, 422–425.

31) Dress, J. C., Stone, J. A., Olson, K. R., Meier, K. H., Gelb, A. M. and Wu, A. H. B. (2009) Clinical utility of an LC-MS/MS seizure panel for common drugs involved in drug-induced seizures. Clin. Chem., 55, 126–133.

32) Marchei, E., Colone, P., Nastasi, G. G., Calabrò, C., Pellegrini, M., Pacifici, R., Zuccaro, P. and Pichini, S. (2008) On-site screening and GC-MS analysis of cocaine and heroin metabolites in body-packers involved in drug-induced seizures. J. Health Sci., 56, 615–622.

33) Shima, N., Katagi, M. and Tsuchihashi, H. (2009) Direct analysis of conjugate metabolites of methamphetamine, 3,4-methylenedioxymethamphetamine, and their designer drugs in biological fluids. J. Health Sci., 55, 495–502.

34) Ditton, J. (2002) Hair testing: just how accurate is it? Survell. Soc., 1, 86–101.

35) Nakashima, K. (2009) Development of ultra sensitive methods with luminescence detections for determination of biologically active compounds. J. Health Sci., 57, 10–21.

36) Pehrsson, A., Gunnar, T., Engblom, C., Seppä, H., Juma, A. and Lillig, P. (2008) Roadside oral fluid testing: comparison of the results of drugwipe 5 and drugwipe benzodiazepines on-site tests with laboratory confirmation results of oral fluid and whole blood. Forensic Sci. Int., 175, 140–148.

37) Fernández, A., Font, A. M., Fité, M. S., Pagés, M. B. and Adroher, M. P. (2008) Drugs of abuse in saliva of drivers: medical and legal aspect. Revista Española de Medicina Legal, 34, 3–10.

38) Kronstrand, R., Nystrom, I., Forsman, M. and Kall, K. (2010) Hair analysis for drugs in driver’s license regranting. A Swedish pilot study. Forensic Sci. Int., 196, 55–58.

39) Gallardo, E., Barroso, M. and Queiroz, J. A. (2009) LC/MS: A powerful tool in workplace drugs testing. Drug Test. Anal., 1, 109–115.

40) Garcia-Jimenez, S., Heredia-Lezama, K., Bilbao-Marcos, F., Fuentes-Lara, G., Monroy-Noyola, A. and Deciga-Campos, M. (2008) Screening for marijuana and cocaine abuse by immunoanalysis and gas chromatography. Ann. N. Y. Acad. Sci., 1139, 422–425.

41) Dress, J. C., Stone, J. A., Olson, K. R., Meier, K. H., Gelb, A. M. and Wu, A. H. B. (2009) Clinical utility of an LC-MS/MS seizure panel for common drugs involved in drug-induced seizures. Clin. Chem., 55, 126–133.

42) Marchei, E., Colone, P., Nastasi, G. G., Calabrò, C., Pellegrini, M., Pacifici, R., Zuccaro, P. and Pichini, S. (2008) On-site screening and GC-MS analysis of cocaine and heroin metabolites in body-packers involved in drug-induced seizures. J. Health Sci., 56, 615–622.
29) Kriger, S., Gunn, J. and Terrell, A. R. (2010) Identification and quantitation of cocaine, benzoylecgonine, and cocaethylene in blood, serum, and plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS). *Methods Mol. Biol.*, **603**, 157–164.

30) Shakleya, D. M., Dams, R., Choo, R. E., Jones, H. and Huestis, M. A. (2010) Simultaneous liquid chromatography-mass spectrometry quantification of urinary opiates, cocaine, and metabolites in opiate-dependent pregnant women in methadone-maintenance treatment. *J. Anal. Toxicol.*, **34**, 17–25.

31) Nieddu, M., Boatto, G., Pirisi, M. A. and Dessi, G. (2010) Determination of four thiophenethylamine designer drugs (2C-T-4, 2C-T-8, 2C-T-13, 2C-T-17) in human urine by capillary electrophoresis/mass spectrometry. *Rapid Commun. Mass Spectrom.*, **24**, 2357–2362.

32) Nieddu, M., Boatto, G., Pirisi, M. A. and Dessi, G. (2010) A rapid method for determination of four thioamphetamines designer drugs (ALEPH-4, ALEPH-8, ALEPH-13, ALEPH-17) in human urine. *J. Liq. Chromatogr. Relat. Technol.*, **33**, 1351–1358.

33) Hidvegi, E. and Somogyi, G. P. (2010) Detection of cannabigerol and its presumptive metabolite in human urine after Cannabis consumption. *Pharmazie*, **65**, 408–411.

34) Crooks, C. R. and Brown, S. (2010) Roche DAT immunoassay: Sensitivity and specificity testing for amphetamines, cocaine, and opiates in oral fluid. *J. Anal. Toxicol.*, **34**, 103–109.

35) Badawi, N., Simonsen, K. W., Steentoft, A., Bernhoft, I. M. and Linnet, K. (2011) Simultaneous screening and quantification of 29 drugs of abused in oral fluid by solid-phase extraction and ultraperformance LC-MS/MS. *Clin. Chem.*, **55**, 2004–2018.

36) Pil, K. and Verstraete, A. (2008) Current developments in drug testing in oral fluid. *Ther. Drug Monit.*, **30**, 196–202.

37) Fritch, D., Blum, K., Nonnemacher, S., Hagerthy, B. J., Sullivan, M. P. and Cone, E. J. (2009) Identification and quantitation of amphetamines, cocaine, opiates, and phencyclidine in oral fluid by liquid chromatography-tandem mass spectrometry. *J. Anal. Toxicol.*, **33**, 569–577.

38) Kala, S. V., Harris, S. E., Freijo, T. D. and Gerlich, S. (2008) Validation of analysis of amphetamines, opiates, phencyclidine, cocaine, and benzoylecgonine in oral fluids by liquid chromatography-tandem mass spectrometry. *J. Anal. Toxicol.*, **32**, 605–611.

39) Wang, I.-T., Feng, Y.-T. and Chen, C.-Y. (2010) Determination of 17 illicit drugs in oral fluid isotope dilution ultra-high performance liquid chromatography/tandem mass spectrometry with three atmospheric pressure ionizations. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.*, **878**, 3095–3105.

40) Concheiro, M., Gray, T. R., Shkleya, D. M. and Huestis, M. A. (2010) High-throughput simultaneous analysis of buprenorphine, methadone, cocaine, opiates, nicotine, and metabolites in oral fluid by liquid chromatography tandem mass spectrometry. *Anal. Bioanal. Chem.*, **398**, 915–924.

41) Schwope, D. M., Milman, G. and Huestis, M. A. (2010) Validation of an enzyme immunoassay for detection and semiquantification of cannabinoids in oral fluid. *Clin. Chem.*, **56**, 1007–1014.

42) Strano-Rossi, S., Colamonici, C. and Botrè, F. (2008) Parallel analysis of stimulants in saliva and urine by gas chromatography/mass spectrometry: perspectives for “in competition” anti-doping analysis. *Anal. Chim. Acta*, **606**, 217–222.

43) Hegstad, S., Khiabani, H. Z., Kristoffersen, L., Kunøe, L., Lobmaier, P. P. and Christophersen, A. S. (2008) Drug screening of hair by liquid chromatography-tandem mass spectrometry. *J. Anal. Toxicol.*, **32**, 364–372.

44) Pelander, A., Ristimaa, J., Rasanen, I., Vuori, E. and Ojanpera, I. (2008) Screening for basic drugs in hair of drug addicts by liquid chromatography/time-of-flight mass spectrometry. *Ther. Drug Monit.*, **30**, 717–724.

45) Tabernero, M. J., Felli, M. L., Nervejo, A. M. and Chiarotti, M. (2009) Determination of ketamine and amphetamines in hair by LC-MS/MS. *Anal. Bioanal. Chem.*, **395**, 2547–2557.

46) Mercolini, L., Mandrioli, R., Saladini, B., Conti, M., Baccini, C. and Raggi, M. A. (2008) Quantitative analysis of cocaine in human hair by HPLC with fluorescence detection. *J. Pharm. Biomed. Anal.*, **48**, 456–461.

47) Miller, E. I., Wylie, F. M. and Oliver, J. S. (2008) Simultaneous detection and quantification of amphetamines, diazepam and its metabolites, cocaine and its metabolites, and opiates in hair by LC-ESI-MS-MS using a single extraction method. *J. Anal. Toxicol.*, **32**, 457–469.

48) Quintela, O., Lendoiro, E., Cruz, A., de Castro, A., Quevedo, A., Jurado, C. and Lopez-Rivadulla, M. (2010) Hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC-MS/MS) determination of cocaine and its metabolites benzoylecgonine, eckgonine methyl ester, and cocaethylene in hair samples. *Anal. Bioanal. Chem.*, **396**, 1703–1712.
49) Huang, D.-K., Liu, C., Huang, M.-K. and Chien, C.-S. (2009) Simultaneous determination of morphine, codeine, 6-acetylmorphine, cocaine and benzoylecgonine in hair by liquid chromatography/electrospray ionization tandem mass spectrometry. *Rapid Commun. Mass Spectrom.*, 23, 957–962.

50) Kintz, P. and Mangin, P. (1995) What constitutes a positive result in hair analysis: proposal for the establishment of cut-off values. *Forensic Sci. Int.*, 70, 3–11.

51) Barroso, M., Dias, M., Vieira, D. N., Queiroz, J. A. and Lopez-Rivadulla, M. (2008) Development and validation of an analytical method for the simultaneous determination of cocaine and its main metabolite, benzoylecgonine, in human hair by gas chromatography/mass spectrometry. *Rapid Commun. Mass Spectrom.*, 22, 3320–3326.

52) Meng, P., Zhu, D., He, H., Wang, Y., Guo, F. and Zhang, L. (2009) Determination of amphetamines in hair by GC/MS after small-volume liquid extraction and microwave derivatization. *Anal. Sci.*, 25, 1115–1118.

53) Johanson, S. S. and Jomil, J. (2009) Determination of amphetamine, methamphetamine, MDA and MDMA in human hair by GC-EI-MS after derivatization with perfluorooctanoyl chloride. *Scand. J. Clin. Lab. Invest.*, 69, 113–120.

54) Kim, J. Y., Shin, S. H., Lee, J. I. and In, M. K. (2010) Rapid and simple determination of psychotropic phenylalkylamine derivatives in human hair by gas chromatography-mass spectrometry using micro-pulverized extraction. *Forensic Sci. Int.*, 196, 43–50.

55) Merola, G., Gentili, S., Tagliaro, F. and MacChia, T. (2010) Determination of different recreational drugs in hair by HS-SPME and GC/MS. *Anal. Bioanal. Chem.*, 397, 2987–2995.

56) Emidio, E. S., Prata, V. de M. and Dorea, H. S. (2010) Validation of an analytical method for analysis of cannabinoids in hair by headspace solid-phase microextraction and gas chromatography-ion trap tandem mass spectrometry. *Anal. Chim. Acta*, 670, 63–71.

57) Hoelzle, C., Scheufler, F., Uhl, M., Sachs, H. and Thiemer, D. (2008) Application of discriminant analysis to differentiate between incorporation of cocaine and its congeners into hair and contamination. *Forensic Sci. Int.*, 176, 13–18.

58) Hill, V., Cairns, T. and Schaffer, M. (2008) Hair analysis for cocaine: factors in laboratory contamination studies and their relevance to proficiency sample preparation and hair testing practices. *Forensic Sci. Int.*, 176, 23–33.

59) De Castro, A., Conceilo, M., Shakleya, D. M. and Huestis, M. A. (2009) Development and validation of a LC/MS assay for the simultaneous quantification of methadone, cocaine, opiates and metabolites in human umbilical cord. *J. Chromatogr. B Biomed. Sci. Appl.*, 877, 3065–3071.

60) Montgomery, D., Plate, C., Alder, S. C., Jones, M., Jones, J. and Christensen, R. D. (2006) Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium. *J. Perinatol.*, 26, 11–14.

61) Jones, J., Rios, R., Jones, M., Lewis, K. and Plate, C. (2009) Determination of amphetamine and methamphetamine in umbilical cord using liquid chromatography-tandem mass spectrometry. *J. Chromatogr. B Biomed. Sci. Appl.*, 877, 3701–3706.

62) Joya, X., Pujadas, M., Falcon, M., Civit, E., Garcia-Algar, W., Vall, O., Pichini, S., Luna, A. and de la Torre, R. (2010) Gas chromatography-mass spectrometry assay for the simultaneous quantification of drugs of abuse in human placenta at 12th week of gestation. *Forensic Sci. Int.*, 196, 38–42.

63) De Castro, A., Concheiro, M., Shakleya, D. M. and Huestis, M. A. (2009) Simultaneous quantification of methadone, cocaine opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry. *J. Anal. Toxicol.*, 33, 243–252.

64) Gray, T. R., Shakleya, D. M. and Huestis, M. A. (2009) A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. *Anal. Bioanal. Chem.*, 393, 1977–1990.

65) Gunn, J. A., Sweeney, B., Dahn, T., Bell, S., Newhouse, R. and Terrell, A. R. (2008) Simultaneous quantification of amphetamine and methamphetamine in meconium using ISOLUTE HM-N-supported liquid extraction columns and GC-MS. *J. Anal. Toxicol.*, 32, 485–490.

66) Lopez, P., Bermejo, A. M., Tabernero, M. J., Cabarcos, P., Alvarez, I. and Fernandez, P. (2009) Cocaine and opiates use in pregnancy: Detection of drugs in neonatal meconium and urine. *J. Anal. Toxicol.*, 33, 351–355.

67) Gunn, J., Kriger, S. and Terrell, A. R. (2010) Detection and quantification of cocaine and benzoylecgonine in meconium using solid phase extraction and UPLC/MS/MS. *Methods Mol. Biol.*, 603, 165–174.

68) Mora, A., Arroyo, A. and Sanchez, M. (2008) Post-mortem Toxicology: Analytical study of cocaine in brain tissue. *Revista de Toxicología*, 25, 42–47.

69) Shakleya, D. M. and Huestis, M. A. (2009) Simultaneous quantification of nicotine, opioids, cocaine, and metabolites in human fetal postmortem brain by liquid chromatography tandem mass spectrometry.
70) Reich, R. F., Cudzilo, K., Levisky, J. A. and Yost, R. A. (2010) Quantitative MALDI-MS(n) analysis of cocaine in the autopsied brain of a human cocaine user employing a wide isolation window and internal standards. *J. Am. Soc. Mass Spectrom.*, 21, 564–571.

71) Colucci, A. P., Aventaggiato, L., Centrone, M. and Gagleano-Candela, R. (2010) Validation of an extraction and gas chromatography-mass spectrometry quantification method for cocaine, methadone, and morphine in postmortem adipose tissue. *J. Anal. Toxicol.*, 34, 342–346.

72) Concheiro, M., Shakleya, D. M. and Huestis, M. A. (2010) Simultaneous analysis of buprenorphine, methadone, cocaine, opiates and nicotine metabolites in sweat by liquid chromatography tandem mass spectrometry. *Anal. Bioanal. Chem.*, 400, 69–78.

73) Berchtold, C., Meier, L. and Zenobi, R. (2011) Evaluation of extractive electrospray ionization and atmospheric pressure chemical ionization for the detection of narcotics in breath. *Int. J. Mass Spectrom.*, 299, 145–150.

74) Kim, J. Y., Shin, S. H. and In, M. K. (2010) Determination of amphetamine-type stimulants, ketamine and metabolites in fingernails by gas chromatography-mass spectrometry. *Forensic Sci. Int.*, 194, 108–114.

75) Lemos, N. P., Anderson, R. A. and Robertson, J. R. (1999) Nail analysis for drugs of abuse: extraction and determination of cannabis in fingernails by RIA and GC-MS. *J. Anal. Toxicol.*, 23, 147–152.

76) Alfazil, A. A. and Anderson, R. A. (2008) Stability of benzodiazepines and cocaine in blood spots stored on filter paper. *J. Anal. Toxicol.*, 32, 511–515.

77) Mercolini, L., Mandrioli, R., Gerra, G. and Raggi, M. A. (2010) Analysis of cocaine and two metabolites in dried blood spots by liquid chromatography with fluorescence detection: A novel test for cocaine and alcohol intake. *J. Chromatogr. A*, 1217, 7242–7248.

78) Popa, D. S., Vlase Leucuta, S. E. and Loghin, F. (2009) Determination of cocaine and benzoylecgonine in human plasma by LC-MS/MS. *Farmacia*, 57, 301–308.

79) Vlase, L., Popa, D. S., Loghin, F. and Leucuta, S. E. (2009) High-throughput toxicological analysis of methamphetamine, MDA and MDMA from human plasma by LC-MS/MS. *Romanian Journal of Legal Medicine*, 17, 213–220.

80) Kiss, B., Popa, D. S., Bojita, M. and Lighin, F. (2009) Development and validation of a HPLC-DAD/FLD method for the determination of MDMA, MDA, methamphetamine, morphine, morphine-glucuronides and 6-monoacetylmorphine in human plasma. *Revue Roumaine de Chimie*, 54, 833–840.